Show simple item record

dc.contributor.authorSoslow, Robert A.
dc.contributor.authorTornos, Carmen
dc.contributor.authorPark, Kay J.
dc.contributor.authorMalpica, Anais
dc.contributor.authorMatias-Guiu, Xavier
dc.contributor.authorOliva, Esther
dc.contributor.authorParkash, Vinita
dc.contributor.authorCarlson, Joseph A.
dc.contributor.authorMcCluggage, W. Glenn
dc.contributor.authorGilks, C. Blake
dc.date.accessioned2020-03-20T13:02:00Z
dc.date.available2020-03-20T13:02:00Z
dc.date.issued2019
dc.identifier.issn0277-1691
dc.identifier.urihttp://hdl.handle.net/10459.1/68287
dc.description.abstractIn this review, we sought to address 2 important issues in the diagnosis of endometrial carcinoma: how to grade endometrial endometrioid carcinomas and how to incorporate the 4 genomic subcategories of endometrial carcinoma, as identified through The Cancer Genome Atlas, into clinical practice. The current International Federation of Gynecology and Obstetrics grading scheme provides prognostic information that can be used to guide the extent of surgery and use of adjuvant chemotherapy or radiation therapy. We recommend moving toward a binary scheme to grade endometrial endometrioid carcinomas by considering International Federation of Gynecology and Obstetrics defined grades 1 and 2 tumors as "low grade" and grade 3 tumors as "high grade." The current evidence base does not support the use of a 3-tiered grading system, although this is considered standard by International Federation of Gynecology and Obstetrics, the American College of Obstetricians and Gynecologists, and the College of American Pathologists. As for the 4 genomic subtypes of endometrial carcinoma (copy number low/p53 wild-type, copy number high/p53 abnormal, polymerase E mutant, and mismatch repair deficient), which only recently have been identified, there is accumulating evidence showing these categories can be reproducibly diagnosed and accurately assessed based on biopsy/curettage specimens as well as hysterectomy specimens. Furthermore, this subclassification system can be adapted for current clinical practice and is of prognostic significance independent of conventional variables used for risk assessment in patients with endometrial carcinoma (eg, stage). It is too soon to recommend the routine use of genomic classification in this setting; however, with further evidence, this system may become the basis for the subclassification of all endometrial carcinomas, supplanting (partially or completely) histotype, and grade. These recommendations were developed from the International Society of Gynecological Pathologists Endometrial Carcinoma project.ca_ES
dc.language.isoengca_ES
dc.publisherLippincott, Williams & Wilkinsca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1097/PGP.0000000000000518ca_ES
dc.relation.ispartofInternational Journal of Gynecological Pathology, 2019, vol. 38, p. S64–S74ca_ES
dc.rightscc-by (c) International Society of Gynecological Pathologists, 2019ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectEndometrial cancerca_ES
dc.subjectFIGO gradeca_ES
dc.subjectThe Cancer Genome Atlasca_ES
dc.subjectTCGAca_ES
dc.subjectGenomic subtypeca_ES
dc.titleEndometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologistsca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.1097/PGP.0000000000000518


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by (c) International Society of Gynecological Pathologists, 2019
Except where otherwise noted, this item's license is described as cc-by (c) International Society of Gynecological Pathologists, 2019